

# Harriet E Gee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1147948/publications.pdf>

Version: 2024-02-01

24  
papers

1,798  
citations

623188

14  
h-index

713013

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

3711  
citing authors

#	ARTICLE	IF	CITATIONS
1	microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 5635-5645.	0.4	285
2	MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU. <i>PLoS ONE</i> , 2010, 5, e10345.	1.1	276
3	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. <i>British Journal of Cancer</i> , 2011, 104, 1168-1177.	2.9	244
4	hsa-miR-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. <i>Cancer</i> , 2010, 116, 2148-2158.	2.0	215
5	Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. <i>Histopathology</i> , 2016, 69, 25-34.	1.6	177
6	MicroRNA-10b and breast cancer metastasis. <i>Nature</i> , 2008, 455, E8-E9.	13.7	134
7	miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense. <i>Cancer Research</i> , 2018, 78, 501-515.	0.4	105
8	HypoxamiRs and Cancer: From Biology to Targeted Therapy. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 1220-1238.	2.5	102
9	Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. <i>Journal of Molecular Medicine</i> , 2013, 91, 749-758.	1.7	64
10	Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. <i>BMC Cancer</i> , 2016, 16, 86.	1.1	51
11	Contouring consensus guidelines in breast cancer radiotherapy: Comparison and systematic review of patterns of failure. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 102-115.	0.9	28
12	<i>In vivo</i> dosimetric impact of breast tissue expanders on post-mastectomy radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 138-145.	0.9	27
13	Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7265.	1.8	26
14	MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1104-1114.	0.4	18
15	A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 40-59.	0.4	14
16	Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. <i>Scientific Reports</i> , 2020, 10, 10226.	1.6	10
17	Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2019, 2019, 1-12.	0.6	9
18	Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial. <i>BMC Cancer</i> , 2021, 21, 940.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Impact of <sc>DNA</sc> damage response defects in cancer cells on response to immunotherapy and radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 546-559.	0.9	5
20	High-Risk Cutaneous Squamous Cell Carcinoma. Current Otorhinolaryngology Reports, 2018, 6, 120-128.	0.2	2
21	Radiation therapy in the prevention and management of brain metastases in patients with small cell lung cancer: a narrative review. Chinese Clinical Oncology, 2021, .	0.4	1
22	DIPG-17. IMPROVING THE RADIOSENSITIVITY OF DIFFUSE INTRINSIC PONTINE GLIOMAS BY MODULATING BIOENERGETIC PATHWAYS. Neuro-Oncology, 2019, 21, ii72-ii72.	0.6	0
23	Are signatures of radiosensitivity ready for routine clinical use? A pragmatic comparison of clinical, pathological, and gene signature predictors of outcome in oropharynx head and neck cancers.. Journal of Clinical Oncology, 2018, 36, e18046-e18046.	0.8	0
24	DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG). Neuro-Oncology, 2020, 22, iii289-iii289.	0.6	0